Pluri (PLUR)
NASDAQ:PLUR
Top Page
Pluri
(NASDAQ:PLUR)
Select Model
Select Model
Rating:40Underperform
Price Target:
$3.00
▼(-13.04% Downside)
Action:DowngradedDate:01/23/26
The score is driven primarily by weak financial performance (minimal and declining revenue, large losses, heavy cash burn, and negative equity with meaningful debt). Technicals are also unfavorable with a clear downtrend and negative MACD. Valuation is constrained by negative earnings, and the Nasdaq noncompliance notice adds a significant listing-risk overhang.
Positive Factors
Revenue Growth
Strong revenue growth indicates successful commercialization of Pluri's technologies, enhancing its market position and potential for future profitability.
Negative Factors
Financial Instability
Financial instability with negative equity and high debt levels poses solvency risks, potentially limiting Pluri's ability to invest in growth opportunities.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Strong revenue growth indicates successful commercialization of Pluri's technologies, enhancing its market position and potential for future profitability.
Read all positive factors
Pluri (PLUR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$33.37M
Dividend YieldN/A
Average Volume (3M)8.39K
Price to Earnings (P/E)―
Beta (1Y)0.84
Revenue Growth121.74%
EPS Growth24.75%
CountryUS
Employees106
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding10,050,743
10 Day Avg. Volume13,380
30 Day Avg. Volume8,388
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)-4.58
Price to Sales (P/S)23.48
P/FCF Ratio-1.58
Enterprise Value/Market Cap1.91
Enterprise Value/Revenue47.52
Enterprise Value/Gross Profit223.26
Enterprise Value/Ebitda-2.44
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Pluri Business Overview & Revenue Model
Company Description
Pluri Inc., a biotechnology company, focuses on the development of placenta-based cell therapy product candidates for the treatment of multiple inflammatory, muscle injuries, and hematologic conditions. The company develops placental expanded (PLX...
How the Company Makes Money
Pluri generates revenue through multiple streams, primarily by commercializing its proprietary technologies and cell therapy products. The company licenses its technology to pharmaceutical and biotechnology firms, which pay upfront fees and ongoin...
Pluri Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
12
Very Negative
Cash Flow
16
Very Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.34M | 1.34M | 326.00K | 287.00K | 234.00K | 0.00 |
| Gross Profit | 285.00K | 654.00K | 322.00K | 278.00K | -819.00K | -1.37M |
| EBITDA | -26.08M | -22.07M | -20.23M | -27.68M | -39.43M | -48.42M |
| Net Income | -26.14M | -22.58M | -20.89M | -28.32M | -41.24M | -49.87M |
Balance Sheet | ||||||
| Total Assets | 30.60M | 38.68M | 39.53M | 50.80M | 68.06M | 93.54M |
| Cash, Cash Equivalents and Short-Term Investments | 12.71M | 20.61M | 30.24M | 40.17M | 55.02M | 64.95M |
| Total Debt | 40.78M | 34.05M | 29.61M | 29.91M | 28.80M | 24.58M |
| Total Liabilities | 39.81M | 39.55M | 34.11M | 35.50M | 35.88M | 36.39M |
| Stockholders Equity | -14.61M | -6.84M | 96.00K | 13.36M | 30.04M | 57.15M |
Cash Flow | ||||||
| Free Cash Flow | -22.01M | -19.83M | -18.34M | -23.12M | -36.78M | -31.28M |
| Operating Cash Flow | -20.15M | -18.21M | -18.02M | -22.86M | -36.50M | -30.91M |
| Investing Cash Flow | 5.30M | 8.03M | 10.58M | 9.70M | 11.78M | -7.26M |
| Financing Cash Flow | 12.38M | 9.53M | 8.84M | 8.02M | 7.50M | 61.40M |
Pluri Technical Analysis
Negative
3.45
Price Trends
3.43
Negative
3.35
Negative
4.03
Negative
Market Momentum
>-0.01
Negative
50.34
Neutral
59.45
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PLUR, the sentiment is Negative. The current price of 3.45 is above the 20-day moving average (MA) of 3.27, above the 50-day MA of 3.43, and below the 200-day MA of 4.03, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 50.34 is Neutral, neither overbought nor oversold. The STOCH value of 59.45 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PLUR.
Pluri Risk Analysis
Pluri disclosed 45 risk factors in its most recent earnings report. Pluri reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Pluri Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | $82.25M | -2.08 | -291.42% | ― | ― | 61.23% | |
52 Neutral | $106.75M | -0.98 | -55.04% | ― | ― | 44.59% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | $29.83M | -9.21 | -96.36% | ― | -6.51% | 58.31% | |
40 Underperform | $33.37M | -1.06 | 280.42% | ― | 121.74% | 24.75% |
* Healthcare Sector Average
PLUR
Pluri
3.34
-0.39
-10.46%
IGC
IGC Pharma
0.30
<0.01
2.41%
PYPD
PolyPid
4.40
1.70
62.96%
ANTX
AN2 Therapeutics, Inc.
3.01
1.75
138.89%
Pluri Corporate Events
Delistings and Listing ChangesRegulatory Filings and Compliance
Pluri Faces Nasdaq Noncompliance Notice, Evaluating Listing Options
Negative
Jan 22, 2026
On January 20, 2026, Pluri Inc. disclosed that it had received a notice from Nasdaq stating the company was no longer in compliance with the exchange’s continued listing standards, having fallen below the required $35 million market value of...
Business Operations and StrategyExecutive/Board Changes
Pluri Grants RSUs to Executives and Board Members
Neutral
Dec 9, 2025
On December 4, 2025, Pluri‘s board of directors granted a total of 10,248 restricted stock units (RSUs) to its Chief Executive Officer and Chief Financial Officer, and 2,885 RSUs to board members as part of its 2019 Equity Compensation Plan....
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.